Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tudorza

- PMLiVE

GSK buoyed by FDA panel backing for Advair successor

Committee votes in favour of Breo’s use in respiratory condition COPD

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

- PMLiVE

GSK’s COPD drug Anoro under review in US

FDA accepts new drug application for the LAMA/LABA combination

- PMLiVE

FDA advisors back Boehringer’s COPD drug olodaterol

Committee votes 15 to 1 in favour despite cancer concerns

- PMLiVE

Boehringer launches COPD patient consultation app for HCPs

Extends reach of the calculator tools on its COPD Exchange website

- PMLiVE

IQWiG knocks back Almirall’s Eklira

Decides added benefit of COPD drug is not proven

- PMLiVE

GSK and Theravance file COPD combo for EU approval

Filing for LAMA/LABA combination comes shortly after US submission

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

Forest Labs launches COPD drug Tudorza in US

Enters a market dominated by Boehringer and Pfizer's Spiriva and GSK's Advair

- PMLiVE

Boehringer launches COPD awareness drive in Japan

Social media campaign will target male smokers’ wives and daughters

Almirall appoints first woman to the board

Karin Louise Dorrepaal will serve as an independent board member

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links